Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MÁ, Soberino J, Malfettone A, Schmid P, Cortés J. Pérez-García JM, et al. Among authors: alonso jl. Eur J Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. Eur J Cancer. 2021. PMID: 33794440 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S, Saura C, Ciruelos E, Alonso JL, de la Morena P, Santisteban Eslava M, Gallegos Sancho MI, de Luna A, Dalmau E, Servitja S, Ruiz Borrego M, Chacón JI. González-Santiago S, et al. Among authors: alonso jl. Breast Cancer Res Treat. 2020 Nov;184(2):469-479. doi: 10.1007/s10549-020-05866-1. Epub 2020 Sep 2. Breast Cancer Res Treat. 2020. PMID: 32876911
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
Garcia-Rodriguez J, Fernandez-Gomez JM, Cozar JM, Miñana B, Gomez-Veiga F, Rodriguez-Antolin A; en representación del Grupo Español de Cáncer de Próstata (GESCAP); En representación del del Grupo Español de Cáncer de Próstata (GESCAP). Garcia-Rodriguez J, et al. Actas Urol Esp (Engl Ed). 2020 Apr;44(3):156-163. doi: 10.1016/j.acuro.2019.06.006. Epub 2020 Feb 26. Actas Urol Esp (Engl Ed). 2020. PMID: 32113829 English, Spanish.
Identification of Cryptosporidium parvum and Blastocystis hominis subtype ST3 in Cholga mussel and treated sewage: Preliminary evidence of fecal contamination in harvesting area.
Suarez P, Vallejos-Almirall A, Fernández I, Gonzalez-Chavarria I, Alonso JL, Vidal G. Suarez P, et al. Among authors: alonso jl. Food Waterborne Parasitol. 2023 Dec 9;34:e00214. doi: 10.1016/j.fawpar.2023.e00214. eCollection 2024 Mar. Food Waterborne Parasitol. 2023. PMID: 38188968 Free PMC article.
377 results